abstract |
In the present invention, novel [1,2,4] triazolo [1,5-a] pyridinyl-6-yl-substituted tetrahydroisoquinolines are illustrated. These compounds and crystalline forms SA1 and N-2 are used for the treatment of various neurological and physiological diseases. In the present invention, methods of forming these compounds and crystalline forms SA-1 and N-2 are also described. |